Clinical Trial Update: Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination and posted results for a Phase 1/2 study of rintatolimod plus interferon alpha-2b in cancer patients with COVID-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Ampligen (rintatolimod)
• Intron A (interferon alfa-2b)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-01-13